Danish drugmaker Novo Nordisk has traditionally generated its pipeline mainly from internal R&D, but a new alliance with venture capital firm Flagship Pioneering signals another departure from that strategy.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,